Novel Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion-Selective Inhibitors for Lung Cancer Therapy

This patent describes novel prop-2-ynamide-derived epidermal growth factor receptor (EGFR) inhibitors, which selectively target EGFR exon20 insertion mutations. These EGFR inhibitors exhibit therapeutic potential for the treatment of nonsmall cell lung cancer (NSCLC) and other malignancies driven by EGFR mutations.